Our critical care products are used by emergency medicine physicians, intensive therapy physicians and paramedics around the world. Every day they are helping to save lives and improve long-term patient outcome.
United Kingdom: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Octapharma by telephoning 0845 1300 522.
Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Octapharma in the United Kingdom by telephoning 1890 920 522.
octaplasLG® (known as LG-octaplas™ in Ireland) contains human plasma proteins, and is a pharmaceutically licensed, proven alternative to fresh-frozen plasma. The latest innovation includes the addition of a prion reduction stage to the manufacturing process1 (a 'Ligand Gel' chromatography column) in line with the Committee for Medicinal Products for Human Use (CHMP) position statement on variant Creutzfeldt-Jakob disease2. Additionally, octaplasLG® is NAT-tested for hepatitis E virus (HEV) during manufacture in line with the European Pharmacopoeia for Human Plasma (Pooled and Treated for Virus Inactivation). Only plasma which tests negative for HEV RNA is used in the final product.
Available in standardised 200 ml bags as either A, B, O, or AB blood groups.
The shelf-life of octaplasLG® is four years when stored at ≤ -18°C and protected from light. After thawing octaplasLG® can be stored for up to 24 hours at +2 - 8°C, or 8 hours at room temperature (+20 - 25°C), before use.
1. Neisser-Svae A etal. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated OctaplasLG®. Vox Sanguinis 2009;97(3):266-233.
2. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02/rev1. June 2004 (revised June 2011).
Treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
Treatment of bleeding and perioperative prophylaxis in congenital deficiency of the vitamin K dependent coagulation factors II and X when purified specific coagulation factor product is not available.
Available in vials of:
500 IU coagulation factor IX (25 IU/mL in 20 mL)
1000 IU coagulation factor IX (25 IU/mL in 40 mL)
Two years shelf-life at room temperature (≤25°C).
Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.
Available in vials of:
- 20% albunorm (10g human albumin in 50 ml)
- 20% albunorm (20g human albumin in 100 ml)
- 5% albunorm (5g human albumin in 100 ml)
- 5% albunorm (12.5g human albumin in 250 ml)
- 5% albunorm (25g human albumin in 500 ml)
Three years shelf-life at room temperature (≤25°C).